[go: up one dir, main page]

RU2002102701A - Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition - Google Patents

Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition

Info

Publication number
RU2002102701A
RU2002102701A RU2002102701/15A RU2002102701A RU2002102701A RU 2002102701 A RU2002102701 A RU 2002102701A RU 2002102701/15 A RU2002102701/15 A RU 2002102701/15A RU 2002102701 A RU2002102701 A RU 2002102701A RU 2002102701 A RU2002102701 A RU 2002102701A
Authority
RU
Russia
Prior art keywords
iron oxide
drug
oxide pigment
pharmaceutical composition
stable oral
Prior art date
Application number
RU2002102701/15A
Other languages
Russian (ru)
Other versions
RU2220715C2 (en
Inventor
Казухиро САКО
Тоёхиро САВАДА
Кеиити ЁСИХАРА
Тацунобу ЁСИОКА
Сунсуке ВАТАНАБЕ
Original Assignee
Яманоути Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яманоути Фармасьютикал Ко., Лтд. filed Critical Яманоути Фармасьютикал Ко., Лтд.
Publication of RU2002102701A publication Critical patent/RU2002102701A/en
Application granted granted Critical
Publication of RU2220715C2 publication Critical patent/RU2220715C2/en

Links

Claims (9)

1. Стабильная пероральная фармацевтическая композиция, включающая лекарственное средство, гидрофильное основание и полиэтиленоксид, и которая представляет собой препарат с пролонгированным высвобождением матричного типа, отличающаяся тем, что включает желтый железооксидный пигмент и/или красный железооксидный пигмент в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа.1. A stable oral pharmaceutical composition comprising a drug, a hydrophilic base and polyethylene oxide, and which is a matrix-type sustained release preparation, characterized in that it includes yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with prolonged matrix type release. 2. Стабильная пероральная фармацевтическая композиция по п.1, отличающаяся тем, что количество добавляемого желтого железооксидного пигмента и/или красного железооксидного пигмента составляет не менее чем 0,3% от массы таблетки.2. A stable oral pharmaceutical composition according to claim 1, characterized in that the amount of added yellow iron oxide pigment and / or red iron oxide pigment is not less than 0.3% by weight of the tablet. 3. Стабильная пероральная фармацевтическая композиция по п.1 или 2, отличающаяся тем, что количество добавляемого желтого железооксидного пигмента составляет от 1 до 20 мас.% от массы препарата.3. A stable oral pharmaceutical composition according to claim 1 or 2, characterized in that the amount of added yellow iron oxide pigment is from 1 to 20 wt.% By weight of the drug. 4. Стабильная пероральная фармацевтическая композиция по п.1 или 2, отличающаяся тем, что количество добавляемого красного железооксидного пигмента составляет от 5 до 20 мас.% от массы препарата.4. A stable oral pharmaceutical composition according to claim 1 or 2, characterized in that the amount of added red iron oxide pigment is from 5 to 20 wt.% By weight of the drug. 5. Способ получения стабильной пероральной фармацевтической композиции, включающий добавление желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид.5. A method of obtaining a stable oral pharmaceutical composition, comprising adding yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising a drug substance, a hydrophilic base and polyethylene oxide. 6. Способ получения стабильной пероральной фармацевтической композиции по п.5, отличающийся тем, что в указанный препарат добавляют желтый железооксидный пигмент с использованием, по меньшей мере, одного способа, выбранного из группы, состоящей из нанесения покрытия, гранулирования и перемешивания.6. A method of obtaining a stable oral pharmaceutical composition according to claim 5, characterized in that yellow iron oxide pigment is added to said preparation using at least one method selected from the group consisting of coating, granulation and mixing. 7. Способ получения стабильной пероральной фармацевтической композиции по п.5 или 6, отличающийся тем, что количество добавляемого желтого железооксидного пигмента и/или красного железооксидного пигмента составляет не менее 0,3 мас.% от массы таблетки.7. A method of obtaining a stable oral pharmaceutical composition according to claim 5 or 6, characterized in that the amount of added yellow iron oxide pigment and / or red iron oxide pigment is at least 0.3 wt.% By weight of the tablet. 8. Способ предотвращения изменений в профиле высвобождения лекарственного средства посредством добавления желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид.8. A method of preventing changes in the release profile of a drug by adding yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising the drug, hydrophilic base and polyethylene oxide. 9. Применение желтого железооксидного пигмента и/или красного железооксидного пигмента в количестве, эффективном для стабилизации препарата с пролонгированным высвобождением матричного типа, включающего лекарственное вещество, гидрофильное основание и полиэтиленоксид для предотвращения изменений профиля высвобождения лекарственного препарата.9. The use of yellow iron oxide pigment and / or red iron oxide pigment in an amount effective to stabilize the drug with a sustained release matrix type comprising a drug, a hydrophilic base and polyethylene oxide to prevent changes in the release profile of the drug.
RU2002102701/15A 1999-08-04 2000-08-01 Stable peroral gel-forming pharmaceutical composition, method for it preparing, method for prevention alteration in medicinal agent releasing, method for enhancement of physical stability of peroral composition RU2220715C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14722299P 1999-08-04 1999-08-04
US60/147,222 1999-08-04

Publications (2)

Publication Number Publication Date
RU2002102701A true RU2002102701A (en) 2003-11-10
RU2220715C2 RU2220715C2 (en) 2004-01-10

Family

ID=22520720

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002102701/15A RU2220715C2 (en) 1999-08-04 2000-08-01 Stable peroral gel-forming pharmaceutical composition, method for it preparing, method for prevention alteration in medicinal agent releasing, method for enhancement of physical stability of peroral composition

Country Status (17)

Country Link
EP (1) EP1205190B1 (en)
JP (1) JP3462490B2 (en)
KR (1) KR100507400B1 (en)
CN (1) CN1193792C (en)
AT (1) ATE324909T1 (en)
AU (1) AU769807B2 (en)
CA (1) CA2387705C (en)
DE (1) DE60027728T2 (en)
DK (1) DK1205190T3 (en)
ES (1) ES2262528T3 (en)
HU (1) HU229295B1 (en)
MX (1) MXPA02001267A (en)
NO (1) NO331834B1 (en)
PL (1) PL200645B1 (en)
PT (1) PT1205190E (en)
RU (1) RU2220715C2 (en)
WO (1) WO2001010466A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
JP2005162737A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release pharmaceutical composition
JP2005162736A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release pharmaceutical composition
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
RU2253453C1 (en) * 2004-03-15 2005-06-10 Общество с ограниченной ответственностью "ЮНАЛ" Antiinflammatory and antiallergic composition
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
RU2279467C1 (en) * 2005-01-25 2006-07-10 Общество с ограниченной ответственностью "Нурлатский ликеро-водочный завод" Vodka
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
EP2389167A2 (en) * 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
JP5667183B2 (en) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Controlled release dosage form with heat melt extrusion
NZ596668A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Oxidation-stabilized tamper-resistant dosage form
RU2442586C1 (en) * 2009-11-11 2012-02-20 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) Hydrogel anticancer medicament
TR201802207T4 (en) 2010-03-29 2018-03-21 Astellas Pharma Inc Controlled Release Pharmaceutical Composition.
ES2486791T3 (en) 2010-09-02 2014-08-19 Grünenthal GmbH Tamper resistant dosage form comprising an inorganic salt
KR102027912B1 (en) 2011-02-15 2019-10-02 지엘팜텍주식회사 An oral sustained-release triple layer tablet comprising tamsulosin or pharmaceutically acceptable salts thereof
PE20141650A1 (en) 2011-07-29 2014-11-22 Gruenenthal Chemie ALTERATION PROOF TABLET PROVIDING IMMEDIATE RELEASE OF THE DRUG
EA201400172A1 (en) 2011-07-29 2014-06-30 Грюненталь Гмбх SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES
ES2692944T3 (en) 2012-04-18 2018-12-05 Grünenthal GmbH Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (en) 2014-05-12 2017-03-06 Gruenenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol.
CN106456550A (en) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 Multiparticles safeguarded against ethanolic dose-dumping
ES2821733T3 (en) 2015-03-19 2021-04-27 Daiichi Sankyo Co Ltd Solid preparation containing dye
KR102426821B1 (en) 2015-03-19 2022-07-28 다이이찌 산쿄 가부시키가이샤 Solid preparation containing antioxidant
BR112017021475A2 (en) 2015-04-24 2018-07-10 Gruenenthal Gmbh tamper-resistant dosage form with immediate release and resistance to solvent extraction
TWI722988B (en) 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 Slow-release pharmaceutical composition and preparation method thereof
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
ES2943883T3 (en) 2018-07-30 2023-06-16 Daiichi Sankyo Co Ltd Solid drug formulation containing stabilizer
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194389C (en) * 1984-06-14 2002-03-04 Novartis Ag Process for preparing a solid dispersion of a pharmaceutically active agent that has low water solubility in a solid matrix of a water-soluble polyalkylene glycol as a carrier.
ZA87279B (en) * 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
JP2820829B2 (en) * 1991-03-07 1998-11-05 武田薬品工業株式会社 Nucleated powder and production method thereof
JPH04346929A (en) * 1991-05-22 1992-12-02 Takada Seiyaku Kk Bromocriptine mesylate preparation having stability to light
DE69619979T2 (en) * 1995-04-14 2002-11-21 Pharma Pass, Illkirch Graffenstaden SOLID COMPOSITIONS WITH A NON-AMORPHOUS ACTIVE SUBSTANCE AND POLYETHYLENE OXIDE
RU2092161C1 (en) * 1995-06-23 1997-10-10 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Agent exhibiting the regulated pentoxyphylline release
PT991409E (en) * 1997-08-01 2002-06-28 Elan Corp Plc COMPOSITIONS OF CONTROLLED LIBERATION CONTAINING TIAGABINE
ATE241341T1 (en) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd STABILIZED PHARMACEUTICAL COMPOSITION

Similar Documents

Publication Publication Date Title
RU2002102701A (en) Stable oral hydrogel-forming, pharmaceutical composition, method for its preparation, method for preventing changes in drug release, method for increasing physical stability of the oral composition
CA2387705A1 (en) Stable pharmaceutical composition for oral use
ATE235234T1 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING MESALAZINE
KR900013943A (en) Drug-Release Control Coatings for Long-acting Preparations
BR9808933A (en) Composition in the form of microcapsules or implants, process for the preparation of a water-soluble substance, active substance, triptorelin acetate, lanreotide acetate, or octreotide acetate, and double-stranded rna
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
CA2025703A1 (en) Pulsatile once-a-day delivery systems for minocycline
MA26859A1 (en) DOSAGE FORM OF MEDICINE CONTROLLED BY A HYDROGEL.
EA200000584A3 (en) Solid thermoformable controlled-release pharmaceutical composition
DE3872739D1 (en) SLOW RELEASE MEDICINAL PRODUCTS.
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2003002091A3 (en) Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
WO2004108162A3 (en) Controlled release pharmaceutical composition
CA2534664A1 (en) Modafinil compositions
ATE253354T1 (en) CAPSULES WITH COMPOSITIONS CONTAINING LORATADINE AND PSEUDOEPHEDRINE
MXPA04003506A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
SE0001916D0 (en) Novel formulation
CA2299464A1 (en) Controlled release pharmaceutical compositions containing tiagabine
JPS5668619A (en) Nifedipine-containing solid composition
WO2003043610A3 (en) A process for manufacture of a sustained release composition containing microbe
RU2003125674A (en) LIQUID PHARMACEUTICAL COMPOSITION
TH27939B (en) Pharmacy ingredient formula
TH18160A (en) Ipsapirone drug formula
TH59782A3 (en) Controlled release galantamine mixtures